R&D channel feed

Play­ing catch-up, Re­gen­eron and Sanofi push ahead on piv­otal PD-1 can­cer stud­ies

9 years ago

Acor­da preps FDA fil­ing af­ter Parkin­son’s drug hits the pri­ma­ry end­point in PhI­II

9 years ago

Bay­er, J&J wrap pos­i­tive PhI­II car­dio study for Xarel­to ear­ly, look­ing to beef up its mar­ket

9 years ago

Lund­beck reads last rites on an­oth­er failed PhI­II Alzheimer’s pro­gram

9 years ago

Cel­lec­tis preps for ground­break­ing US tri­als for an off-the-shelf CAR-T ther­a­py

9 years ago

Bris­tol-My­ers part­ner In­nate con­cedes a PhII flop for I/O drug lir­ilum­ab in fight­ing AML

9 years ago

Af­ter promis­ing Trump new US jobs, Eli Lil­ly sets out to chop 200 R&D staffers

9 years ago

Am­gen scores pos­i­tive PhI­II car­dio out­comes for its PC­SK9 fran­chise drug Repatha

9 years ago

Avi­ra­gen shares plunge as RSV an­tivi­ral flunks a small PhI­Ia study

9 years ago

Strug­gling Oph­thotech or­ga­nizes a glob­al hunt for some new opthal­mol­o­gy deals

9 years ago

Cataba­sis shares are shred­ded af­ter lead drug flops in PhII Duchenne MD study

9 years ago

Eli Lil­ly shut­ters the last PhI­II so­la study, cer­tain of fail­ure

9 years ago

Tenax en­dures (an­oth­er) clin­i­cal cat­a­stro­phe as its PhI­II flops, shares blitzed

9 years ago

Af­ter a PhII cat­a­stro­phe wiped out a bil­lion dol­lars in mar­ket cap, Seres is look­ing for a do-over

9 years ago

Mi­cro­cap biotech Ocera craters on a PhI­Ib fail­ure for he­pat­ic en­cephalopa­thy

9 years ago

Fi­bro­Gen, As­traZeneca ready Chi­na ap­pli­ca­tion as ane­mia drug scores in two piv­otal stud­ies

9 years ago
China
Pharma

No­vo Nordisk shrugs off Brex­it, un­veils $144M plan for a di­a­betes re­search cen­ter at Ox­ford

9 years ago
Financing

Reg­u­lus or­dered to re­main in lim­bo as FDA re­fus­es to lift hold, de­mand­ing more da­ta on lead drug

9 years ago

No­van’s shares in melt­down fol­low­ing "dis­cor­dant" PhI­II stud­ies of a new ac­ne drug

9 years ago

Ouch: Eli Lil­ly is walk­ing away from Ado­cia deal and its ul­tra-fast in­sulin — for the sec­ond time

9 years ago

High­land who? Biotech gets a $200M war chest to crack the US AD­HD mar­ket

9 years ago

In­ves­ti­ga­tors de­tail some of the hopes – and fears – be­hind Cel­lec­tis' off-the-shelf CAR-T

9 years ago

Ei­sai plots new drug ap­pli­ca­tions in US, Eu­rope and Chi­na af­ter Lenvi­ma scores in head-to-head liv­er can­cer study

9 years ago

Fight­ing a gener­ic on­slaught, No­var­tis adds CAR-T to its grow­ing list of late-stage block­busters

9 years ago
First page Previous page 306307308309310311312 Next page Last page
A service from the Financial Times